Obesity drug RAY1225 put through drug interaction tests
NCT ID NCT07362030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study checks if a new obesity drug, RAY1225, changes how the body processes common medicines like warfarin, atorvastatin, metformin, and digoxin. About 32 healthy adults will take RAY1225 along with these drugs to measure blood levels and watch for side effects. The goal is to gather safety information, not to treat obesity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dongguan People's Hospital
Dongguan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?